Latozinemab, a novel progranulin-elevating therapy for frontotemporal dementia

BACKGROUND: Heterozygous loss-of-function mutations in the progranulin (PGRN) gene (GRN) cause a reduction in PGRN and lead to the development of frontotemporal dementia (FTD-GRN). PGRN is a secreted lysosomal chaperone, immune regulator, and neuronal survival factor that is shuttled to the lysosome...

Descripción completa

Detalles Bibliográficos
Autores principales: Kurnellas, Michael, Mitra, Ananya, Schwabe, Tina, Paul, Robert, Arrant, Andrew E., Roberson, Erik D., Ward, Michael, Yeh, Felix, Long, Hua, Rosenthal, Arnon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268535/
https://www.ncbi.nlm.nih.gov/pubmed/37322482
http://dx.doi.org/10.1186/s12967-023-04251-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268535/
https://www.ncbi.nlm.nih.gov/pubmed/37322482
http://dx.doi.org/10.1186/s12967-023-04251-y

Ejemplares similares